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Background: Supplements to support clinical-grade cultures of mesenchymal stem cells (MSC) are required to
promote growth and expansion of these cells. Platelet lysate (PL) is a human blood component which may replace
animal serum in MSC cultures being rich in various growth factors. Here, we describe a plasma poor pathogen-free
platelet lysate obtained by pooling 12 platelet (PLT) units, to produce a standardized and safe supplement for
clinical-grade expansion of MSC.
Methods: PL lots were obtained by combining 2 6-unit PLT pools in additive solution (AS) following a
transfusional-based procedure including pathogen inactivation (PI) by Intercept technology and 3 cycles of
freezing/thawing, followed by membrane removal. Three PI-PL and 3 control PL lots were produced to compare
their ability to sustain bone marrow derived MSC selection and expansion. Moreover, two further PL, subjected to PI
or not, were also produced starting from the same initial PLT pools to evaluate the impact of PI on growth factor
concentration and capacity to sustain cell growth. Additional PI-PL lots were used for comparison with fetal bovine
serum (FBS) on MSC expansion. Immunoregulatory properties of PI-PL-generated MSC were documented in vitro by
mixed lymphocyte culture (MLC) and peripheral blood mononuclear cells (PBMC) mitogen induced proliferation.
Results: PI-PL and PL control lots had similar concentrations of 4 well-described growth factors endowed with
MSC stimulating ability. Initial growth and MSC expansion by PI-PL and PL controls were comparable either using
different MSC populations or in head to head experiments. Moreover, PI-PL and PL control sustained similar MSC
growth of frozen/thawed MSC. Multilineage differentiation of PI-derived and PI-PL-derived MSC were maintained in
any MSC cultures as well as their immunoregulatory properties. Finally, no direct impact of PI on growth factor
concentration and MSC growth support was observed, whereas the capacity of FBS to sustain MSC expansion in
basic medium was irrelevant as compared to PL and PI-PL.
Conclusion: The replacement of animal additives with human supplements is a basic issue in MSC ex vivo
production. PI-PL represents a standardized, plasma-poor, human preparation which appears as a safe and good
candidate to stimulate MSC growth in clinical-scale cultures.
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Mesenchymal stem cells (MSC) are multipotent progeni-
tors cells with self-replicative and differentiation abilities.
Actually, MSC differentiate into several tissues of meso-
derm lineage, although their potential to give rise to cells
of several embryonic origin as neurons, hepatocytes or
epithelial cells has also been reported [1-3]. With their
plasticity, self-renewal and immunoregulatory capacities
these cells have generated great interest for clinical ap-
plications either in cell therapy aimed to induce immune
tolerance or in tissue engineering [4-11].
MSC are typically obtained from bone marrow (BM),
but they can be also isolated from a variety of other hu-
man sources as adipose tissue, muscle, connective tissue,
dental pulp, cord blood, placenta and amniotic fluid
[12,13]. In BM, MSC are present at a very low frequency
(0.001-0.01%), thus ex-vivo expansion is an essential step
to reach a number of MSC which appears appropriate
for clinical applications. To sustain cell growth, most
clinical-scale MSC production protocols use cocktails
which contain serum of animal origin as supplement.
However, these products maintain the potential risk of
pathogen transmission and immunological reactions re-
lated to the different species origin. Platelet lysate (PL)
contains a wide series of growth factors, thanks to which
platelets (PLT) are capable to mediate tissue repair at in-
jured sites in physio-pathological conditions; for these
reasons it has been proposed as a potential supplement
for MSC cultures. Various studies have demonstrated
that growth factors derived from PL are able to sustain
MSC growth and expansion [14-18] and, since these ob-
servations have been reported, several efforts have been
made to standardize its production. In regard to this
issue, it has to be taken into account that the concentra-
tion of soluble growth factors released by PLT is highly
variable among different individuals. Therefore, PLT
from multiple donors should be required and included
in each preparation to compensate individual variability
and to obtain a more standardized and reproducible PL
product. Pooling PLT obtained by whole blood-derived
buffy-coats is a standardized procedure to produce
pooled PLT concentrates for transfusional use. Consider-
ing that transmission of pathogens via blood transfusion
is still a major threat, plasma or PLT pathogen inactivation
(PI) has been introduced for routine blood component
production at several sites. The innovative technology of
photochemical PI utilizes a synthetic psoralen, as active
compound, which specifically interacts with nucleic acids
when exposed to UVA light, blocking both DNA or RNA
replication. Thus, the technology shows efficacy in inacti-
vating viruses, bacteria, protozoa and eventual residual
leucocytes. Starting from these concepts, we adopted a
PLT pooling procedure followed by an additional step of
photochemical treatment necessary for PI to produce aplasma-poor, pathogen-free PL in a closed sterile system.
The pathogen inactivated PL (PI-PL) preparations were
employed to sustain the growth and the expansion of
MSC from different BM samples. This preparation was
named Mesengen™ by a trademark associated with the
registration of the international patent application of this
product (PCT/IB2012/055062).
Methods
Protocol for clinical-scale preparation of plasma-poor PI-PL
Whole blood was collected from voluntary donors se-
lected following current procedures for blood donation.
Blood units were screened for transfusion transmitted
viruses and other blood-borne pathogens in compliance
with national regulatory requirements. Buffy-coats (BC)
were obtained by centrifugation of whole blood dona-
tions according to the procedures validated in the rou-
tine separation of blood components for transfusional
therapy. Six BC-PLT units were pooled within 24 hours
from collection by using a sterile connector device (SCD -
Composeal, Fresenius Kabi AG, Bad Homburg, Germany)
and a dedicated set for component pooling and produc-
tion (Terumo-Teruflex BP-kit with Imugard III-S-PL,
Terumo, Tokyo, Japan). After centrifugation at 1,300 rpm
for 12 minutes at 22°C (Heraeus Cryofuge 5500i, Thermo
Fisher Scientific, Waltham, MA, USA) PLT were sepa-
rated from BC by using the automatic system Compomat
G4 (Fresenius Kabi AG). The pool of six PLT units under-
went PI procedure by the Intercept technology (Intercept
Blood System for Platelets, Cerus Corporation, Concord,
California, USA). The entire process was performed in a
closed system and based on the following major steps: a)
mixing of PLT pool with psoralen compound (Amatosa-
len; Cerus Corporation), b) illumination with UVA light,
c) removal of residual psoralen and free photoproducts by
means of a compound absorption device (CAD). At the
end of the process, the inactivated PLT were resuspended
in InterSol solution (additive solution, AS; Fenwall Inc.,
Lake Zurich, IL, USA) containing a residual 20-30% of hu-
man plasma (for a total volume of approximately 300 mL),
with a PLT content ranging from 2.5 to 3.5 × 1011. The
clinical-scale process to generate a single lot of a PI-PL is
summarized in Figure 1. In detail, two pools of six PI-PLT
units were connected each other under sterile conditions
to obtain a pool of 12 PI-PLT units, provided that they
had a PLT count equal to 1 × 109/mL or slightly higher.
The final pooled-PLT product was frozen at -80°C and
thawed at 37°C for three consecutive cycles to lyse PLT,
then centrifuged at 4,000 rpm for 30 minutes at room
temperature (Heraeus Cryofuge 6000i, Thermo Fisher
Scientific) to remove PLT membranes. Sterility tests were
performed prior and after the entire procedure of PL
production to exclude aerobic, anaerobic and fungal con-
tamination (BacT/ALERT, Biomerieux SA, Marcy l’Etoile,
Figure 1 PI-PL production process flow-chart. The scheme shows the production process of a single PI-PL lot starting from two pools of 6 PLT
units each. PLT, platelets; AS, additive solution.
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pediatric bags (50 mL per bag) and cryopreserved at -80°C
until use.
Control PL preparations were also produced for com-
parison following the same procedure above described
without including the PI step.
On the whole, 11 PL preparations were tested and
shown in the present work: three inactivated (PI-PL1,
PI-PL2, PI-PL3), three as controls (PL1, PL2, PL3), one
aliquoted in two parallel samples prior PI to obtain a PL
and a PI-PL from the same lot (PL18 and PI-PL18) and
three additional PI-PL to make a comparison with fetal
bovine serum (FBS) on MSC growth (PI-PL11, PI-PL16,
PI-PL43/44). Preparations were tested to compare the
ability of both PL and PI-PL products to sustain growth
and expansion of MSC isolated from BM obtained from
14 different donors.Measurements of PLT derived growth factors in PI-PL and
control PL preparations
The concentration of PLT growth factors, i.e. platelet de-
rived growth factor AB (PDGF-AB), vascular endothelial
growth factor (VEGF), basic-fibroblast growth factor
(bFGF) and transforming growth factor-β1 (TGF-β1, in the
immunoreactive form) was evaluated in triplicate in each
PI-PL and control PL preparation by using commercially
available immunoenzymatic kits: PDGF-AB (Quantikine
Human PDGF-AB, R&D Systems, Minneapolis, Minnesota,
USA), VEGF (Quantikine Human VEGF, R&D System),
bFGF (Quantikine Human FGF basic, R&D System),
TGF-Beta (Quantikine Human TGF-Beta 1, R&D System).
MSC selection from BM and in-vitro expansion
BM derived mononuclear cells (BM-MNC) were ob-
tained by wash-out of BM left over contained in bags
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plantation [19]. Fourteen different BM samples were ob-
tained from as many donors of BM grafts, following a
clinical-scale procedure with GMP-grade reagents. BM
left over contained in bag and filters was washed with
sterile PBS GMP-grade (LiStarFish, Milano, Italy) and
BM-MNC were isolated by density gradient (lymphocyte
separation medium 1,077 GMP-grade, LiStarFish). BM-
MNC were washed twice in PBS GMP-grade additioned
with 2% human albumin (Kedrion S.P.A Lucca, Italy),
counted and suspended at 1 × 106 BM-MNC/mL in culture
medium consisting of D-MEM GMP-grade (LiStarFish)
additioned with 10% PI-PL or 10% PL control. Moreover,
in some experiments BM-MNC were cultured in D-MEM
additioned with 10% FBS (EuroClone, Milan, Italy). The
cells were cultured in T25 or T75 polystyrene flasks (Iwaki,
Asahi Glass Co LTD, Tokyo, Japan) and maintained at
37°C in a humidified atmosphere containing 5% CO2.
After 48 hours the non-adherent cells were removed and
fresh medium added to the cultures. The medium was then
changed twice a week until cells reached a confluence de-
gree of 80% (passage 1, P1), as judged by microscopical
examination at 10× and 4× magnification. At confluence,
cells were detached by trypsin (GMP-grade, Li StarFish)
treatment, harvested, counted and diluted to 4,000 cells/
cm2 for further expansion. In order to avoid the expected
inaccurancy of cell counting by a manual method, MSC
enumeration during cultures was performed by flow cytom-
etry and expressed as absolute count, using monoclonal
antibodies (Mo-Ab) specific for a constitutive antigen of
MSC (CD105) and an additional Mo-Ab, with CD90 or
CD44 specificity, which co-identifies MSC. Briefly, pre-
defined amounts of fluorescent beads were added to a
known volume of cells and counted along with cells by
using a FacsCalibur (Becton-Dickinson San Jose’, California,
USA). Cells were gated on the basis of their physical
features (forward and side scatter signals) and fluorescent
signals. Two replicates counts were performed for each
sample and the average value of replicates was accepted as
the correct absolute cell number.
Once MSC reached confluence in each respective culture
(P1), nascent MSC populations were identified as MSC-1,
MSC-2, MSC-3, MSC-4, MSC-5, MSC-6, MSC-7, MSC-8,
MSC-9, MSC-11, MSC-12, MSC-082, MSC-170 and MSC-
180. Following P1, MSC underwent two further passages
(passage 2 and 3, P2 and P3) and fold expansion was calcu-
lated by dividing the total number of cells obtained at con-
fluence by the number of cells seeded at each passage. At
the end of expansion (P3), aliquots of 2 × 106 MSC were
frozen in D-MEM additioned with 5% human albumin and
10% dymethyl-sulfoxide (DMSO) GMP-grade (LiStarFish)
as final concentration, by using a freezing protocol (Kryo
560-16 Planer; Planer PLC Sunbury-On-Thames, United
Kingdom) validated for cryopreservation of haemopoieticstem cells for clinical transplantation. MSC were cryopre-
served in liquid nitrogen for at least 3 months, then
thawed, washed and checked for viability. After thawing,
15,000 viable MSC/cm2 were cultured again in D-MEM
additioned with the same PL or PI-PL preparations used
for their pre-freezing expansion. At 80% confluence cells
were detached by trypsin treatment, analyzed by flow–cy-
tometry following the previously described analytical strat-
egy and re-expanded to evaluate the ability of MSC to
proliferate and differentiate after cryopreservation from
passage 3 to 4 (P3, P4).
Colony-forming unit-fibroblast (CFU-F) assay
Colony-forming-unit assay was performed by plating
2 × 105 BM-MNC/ml in D-MEM medium additioned
with 10% of PL or 10% of PI-PL. Clusters consisting of
at least 50 cells were counted as a colony under an
inverted microscope.
MSC immunophenotyping
Flow cytometric analysis was performed on starting
samples and at each passage by using the following Mo-
Abs: anti-CD71 (allophycocyanin, APC-conjugated, Becton-
Dickinson), anti-CD73 (phycoerytrhin, PE-conjugated,
Becton-Dickinson), anti-CD90 (allophycocyanin, APC-
conjugated, Becton-Dickinson), anti-CD105 (peridinin
chlorophyll protein complex, PerCP-conjugated, Becton-
Dickinson), anti-CD166 (PE conjugated, Becton-Dickinson),
anti-CD45 (FITC-conjugated, Becton-Dickinson) and anti-
CD34 (FITC-conjugated, Becton-Dickinson).
At the end of the culture time, MSC were checked
for viability by using (7-amino-actinomycin D) 7-AAD
(Becton-Dickinson) and a Mo-Ab identifying CD105,
which represents a MSC constitutive antigen. Viable
MSC were identified as CD45-, CD105+, 7-AAD- cell
events.
MSC immunoregulatory effect
Peripheral blood mononuclear cells (PBMC), from dif-
ferent voluntary donors after informed consent, were
isolated by density gradient and used as responder (R)
and stimulator (S) cells in Mixed Lymphocyte Cultures
(MLC) or in mitogen proliferation assay by phytohaem-
agglutinin (PHA; Gibco, Life Technologies Italia, Monza,
Italy). MSC were added to MLC and PHA-stimulated
lymphocyte culture and the proliferation was evaluted
by flow-cytometric analysis of the cell tracking dye
carboxy-fluorescein di-acetate succinimidyl ester (CFSE;
Invitrogen, Life Technologies). Briefly, 5 × 106 R cells
were stained with CFSE 5 μM and then checked for via-
bility. 1 × 106 viable CFSE+ R cells were cultured with
1 × 106 irradiated S cells at 1/1 ratio in MLC or with
50 μg/mL of PHA, respectively for 7 and 3 days at 37°C
in a humidified atmosphere containing 5% CO2. At
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PL or PI-PL driven expansion process, were added at a
R cells/MSC ratio of 20/1, 10/1, 5/1. Following antigen
or mitogen proliferative stimulus, the stained cells
undergo mitotic events which generate a CFSE dilution
profile. Generational boundaries identify adjacent daugh-
ter peaks which are used to calculate percentage of pro-
liferating cells falling in each daughter peak. The
inhibition of cell proliferation in MLC, as well as in
PHA cultures, was expressed as the percentage of study
R cells (co-cultured with MSC) not moving from 1st
daughter (peak M2, see Figure 2) to 2nd daughter gen-
eration (peak M3), compared to control R cellsFigure 2 Experiments of MSC induced immunosuppressive activity. C
without MSC (a) and with MSC, with R cells to MSC ratio of 20/1 (R/MSC 20/1
daughter proliferating cells and M3 is the peak of 2nd daughter proliferating
1st and 2nd daughter generations either in absence or in presence of differen
cell proliferation in MLC expressed as percentage of study R cells (co-cultured
compared to control R cells (cultured without MSC; see also methods). The ex
PI-PL2-derived MSC8, PL3- and PI-PL3-derived MSC8. PBMC used as R cells in
PHA at a concentration of 50 μg/ml. Data show that with a ratio of R cells to
observed, without any significant difference among MSC populations (as judg
differences between PL- and PI-PL-derived identical MSC populations). Culture
MSC population than the corresponding MLC at R/MSC 20/1. MSC, mesenchy
corresponds to R/MSC 20/1, MSC 100000 to R/MSC 10/1, MSC 200000 to R/M(cultured in the absence of MSC) and was calculated by
the following formula:
% Inhibition ¼ 1‐ % study R cells in M3
% control R cells in M3
 100
Experiments were performed using PL1- or PI-PL1-
derived MSC3, PL2- ,PI-PL2- ,PL3- and PI-PL3-derived
MSC8 (Figure 2).
PBMC and MSC were also co-cultured at a ratio of 5/
1 for 14 days and, at the end of culture, stained with
antibodies against CD4 (FITC-conjugated, Becton-
Dickinson), CD25 (APC-conjugated, Becton-Dickinson)SFE dilution profile of stained responder (R) cells in MLC cultured
) (b). M1 is the peak of cells not proliferating, M2 is the peak of 1st
cells. c) Percentage of R proliferating cells in MLC moving respectively to
t MSC concentrations, in a representative experiment. d) Inhibition of
with MSC) not moving from 1st daughter to 2nd daughter generation,
periments were performed using PL1- and PI-PL1derived MSC3, PL2- and
MLC were also co-cultured at R/MSC 20/1 without stimulator cells with
MSC of 20/1 (R/MSC 20/1) the highest cell proliferation inhibition was
ed by two-tailed paired Student’s T test, specifically applied to assess
s carried out in the presence of PHA produced less inhibition for any
mal stem cells; R, responder cells; S, stimulator cells; MSC 50000
SC 5/1.
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the ability of MSC to stimulate the proliferation of T regu-
latory CD4 + CD25 + FoxP3+ cells (Figure 3) [20].
MSC differentiation assays
The potential of MSC to differentiate into different meso-
dermal lineages was assessed at P3 according to the fol-
lowing protocols:
Osteogenesis - cells were cultured at 20,000 cell/cm2 in
Petri dishes in α-MEM (Invitrogen, Life Technologies)
supplemented with 5% of control PL or 5% of PI-PL,
desamethasone 10-7 M (Sigma-Aldrich, St Louis,
Missouri, USA), ascorbic acid 10-5 M (Sigma-Aldrich),
β-glycerophosphate 10-2 M (Sigma-Aldrich). MSC
unexposed to differentiating factors, were cultured in
α-MEM additioned with either 5% of PL or PI-PL and
used as staining control. After 21 days of culture the
cells were stained with naftol AS-O cloride-acetate and
α-naftil acetate esterase (Sigma-Aldrich) and subjected
to examination by an optical microscope with a magni-
fication of 10× and 40×.
Adipogenesis - cells were cultured at 20,000 cell/cm2 in
Petri dishes in α-MEM (Invitrogen, Life Technologies)
supplemented with 5% of control PL or 5% PI-Pl, desa-
methasone 10-6 M (Sigma-Aldrich), insulin 10 μg/mL
(Sigma-Aldrich), 1-methyl-3-isobutylxhantine 5 × 10-4 MFigure 3 Generation of regulatory T cells by MSC. Expression of CD4 +
with PI-PL3-derived MSC8 (b, d) at a ratio PBMC/MSC 5/1, showing nascen(Sigma-Aldrich), indomethacin 60 μM (Sigma-Aldrich).
Unstimulated MSC cultured in α-MEM additioned either
with 5% of PL or PI-PL were used as staining control.
After 21 days of culture the cells were stained with oil
RED O (Bio-Optica, Milano, Italy) and evaluated by
microscopic examination.
Chondrogenesis - 200,000 cells were cultured in 15 mL
conical tube in α-MEM (Invitrogen, Life Technologies)
supplemented with 5% of control PL or 5% PI-PL,
desamethasone 10-7 M (Sigma-Aldrich), ascorbic acid
10-4 M (Sigma-Aldrich), transforming growth factor-
beta 10 ng/mL (Sigma-Aldrich) and insulin 10 μg/mL
(Sigma-Aldrich). After 21 days of culture, cells were
harvested, fixed with formalin and embedded with
paraffin. Sections were stained with toluidine blue
(Bio-Optica, Milano, Italy) and evaluated by micro-
scopic examination. 200,000 unstimulated MSC were
cultured in Petri dishes in α-MEM additioned either
with 5% of PL or PI-PL and used as staining control.
Karyotypic and statistical analysis
All MSC populations, when reached P1 and P3 (P4 for
frozen/thawed MSC), were cultured at a cell concentra-
tion of 7,000 cells/cm2 in identical culture conditions as
those described above to evaluate karyotypic analysis
according to analytical protocols of the International
System for Human Cytogenetics Nomenclature.CD25+ and CD25 + FoxP3+ in PBMC 14-day cultured without (a, c) or
t regulatory T cells at higher frequency in the presence of MSC.
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Data obtained from growth factor assays, cell growth exper-
iments, flow cytometry and functional studies were com-
pared using two-tailed unpaired, two-tailed paired Student’s
T test, ANOVA and Chi-square for multiple dependent
variables, as appropriate (StatPlus:mac, AnalystSoft Inc.,
Alexandria, Va, USA). A p value < 0.05 was considered
as statistically significant.Results and discussion
Control PL and PI-PL preparations
Six PL preparations were produced by the clinical-scale
procedure, three inactivated (PI-PL1, PI-PL2, PI-PL3)
and three as controls (PL1, PL2, PL3). Additional PL
and PI-PL were then produced by identical procedures
and tested to assess the direct impact of PI on growth fac-
tors and growth-promoting ability (PL18, PI-PL18) and to
compare FBS and PI-PL (PI-PL11, PI-PL16, PI-PL43/44)
effect on MSC growth. All preparations gave negative
cultures at the sterility controls and therefore were used
for MSC selection and expansion protocols.
The concentration of PDGF-AB, VEGF, bFGF and
TGF-β1 released in PL were comparable between PL
control and PI-PL lots and among the different prepara-
tions, suggesting that pooling of 12 PLT units in a single
unit may balance the individual variability of PLT growth
factor release into the final product (Table 1).
Effect of control PL and PI-PL on MSC selection
and expansion
By culturing 5 × 106 MNC isolated from BM samples, a
median of 0.931 × 106 MSC (range 0.364 × 106-1.264 × 106)
were obtained within 15 days (range 12-16 days) in all
growth experiments, including all cultures carried out in
the presence of both PL control and PI-PL lots. Figure 4
shows the average magnitude of five MSC (identified as
1,2,3,4,5) growth (from P1 to P3) expressed as doubling
time (DT) which was comparable for PI-PL preparations
and PL controls. Then, MSC6 sample was chosen to testTable 1 Analysis of growth factor concentration by ELISA in d
PL preparations PDGF-AB* (pg/ml) VEGF§ (p
PL1 42,778 ± 10,206 15,666 ±
PL2 32,071 ± 2,525 11,239 ±
PL3 26,272 ± 1,105 10,571 ±
PI-PL1 25,586 ± 1,281 11,276 ±
PI-PL2 35,140 ± 1,624 10,119 ±
PI-PL3 41,299 ± 2.041 11,187 ±
PL platelet lysate, PI-PL pathogen inactivated platelet lysate, PDGF-AB platelet derive
fibroblast growth factor, TGF-beta1 transforming growth factor beta1; means ± stan
growth factor concentration. *p = 0.937, §p = 0.119, °p = 0.009 (in favour of PI-PL), #p
observed in control PL and PI-PL lots.three different PI-PL lots (1,2,3) in comparison with con-
trols PL1, PL2 and PL3. Figure 5 shows as the different PI-
PL preparations exerted a growth effect, expressed as DT
for both P1-P2 and P2-P3 passages, comparable to PL1,
PL2 and PL3 controls and in any case capable of inducing
at least a 90 fold expansion (expressed as the expansion
from P1 to P3 phase; data not shown). An additional ex-
periment was carried out to test the ability of different PI-
PL lots to promote the growth of MSC originating from
the same initial BM-MNC suspension, in a head to head
comparison with PL controls. The comparisons between
the MSC growth by PL and PI-PL lots expressed as fold ex-
pansion and DT are reported in Table 2. Results of this set
of growth experiments carried out on MSC1, MSC3,
MSC4, MSC5, MSC6, MSC7 and MSC8 indicated that the
process of inactivation does not compromise the capacity
of each PI-PL lot to initiate MSC growth (P1) and to pro-
mote expansion at P3, with proper and comparable DT.
On the whole, the results of MSC growth experiments
show that both control PL and PI-PL preparations are able
to exert a proper stimulus for MSC proliferation. On the
contrary, FBS added to D-MEM without other additives
produced an irrelevant effect on MSC culture initiation
and subsequent expansion, as compared to four different
PL/PI-PL lots (PL1, PI-PL11,PI-PL16,PI-PL43/44, Figure 6).
After thawing and washing to remove DMSO, MSC11
MSC12, MSC170, MSC180 and MSC082 showed a cell
viability greater than 80% and the typical MSC surface
phenotype. Thawed cells retained plastic adherence cap-
acity, reaching confluence within 1 week from the start of
culture. Results of MSC growth between passage 3 and 4
after thawing, expressed as DT, are shown in Figure 7.
Both PI-PL and control PL preparations promoted com-
parable cell growth of different thawed MSC populations.
The results of additional growth factor assays and MSC
growth experiments carried out using PL18 and PI-PL18
(these two preparations were obtained from the same ini-
tial lot) are shown in Figure 8. These experiments, show-
ing a direct comparison between PL18 and PI-PL18,ifferent PL and PI-PL preparations
g/ml) bFGF° (pg/ml) TGF-beta1# (pg/ml)
1,257 94.6 ± 6.11 88,590 ± 3,169
673 111.6 ± 1.40 72,694 ± 3,245
514 91.3 ± 3.21 90,637 ± 533
1,108 110 ± 10 63,512 ± 1,500
827 118 ± 2.88 70,626 ± 2,013
757 109 ± 3.60 90,188 ± 1.051
d growth factor AB, VEGF vascular endothelial growth factor, bFGF basic
dard deviations are shown of a triplicate assay performed to detect each
= 0.082 at unpaired two-tailed Student’s T test between concentrations
Figure 4 MSC growth in presence of three different lots of PL and PI-PL. MSC 1,2,3,4,5 were assessed in their growth ability by measuring
doubling time (DT) for each culture experiment, in the presence of PL1,2,3 and PI-PL1,2,3 series. Data are presented as the average ± standard deviation
of DT obtained in the presence of each PL or PI-PL for different MSC populations. Statistical comparison was made by ANOVA which states the absence
of any significant difference among culture series. *Statistical significance was evaluted between the indicated groups by post-hoc Scheffe’s F test.
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PDGF-AB, VEGF, bFGF and TGF-β1 concentrations and
growth of MSC170, MSC180, MSC082 and MSC11.
Cultures were evaluated by karyotypic analysis at P3
(P4 for frozen/thawed MSC) and none abnor-
mality had been revealed according to the analyticalFigure 5 Parallel growth of MSC6 population sustained by PL1, PL2, P
time (DT) from passage 1 to passage 2 (DT P1-P2) and from passage 2 to p
series was 4.14% and 11%, respectively, during P1-P2 passage and 5% and
groups were revealed by Chi-square for multiple dependent variables.protocols of the International System for Human
Cytogenetics Nomenclature (data not shown).
CFU-F assays
The MSC precursor content was found comparable by
culturing BM-MNC in medium additioned with PL orL3 and PI-PL1, PI-PL2, PI-PL3 lots. Data are expressed as doubling
assage 3 (DT P2-P3). Coefficient of variation for PL1,2,3 and PI-PL1,2,3
13%, respectively, during P2-P3 passage. No differences between
Table 2 Comparisons between control PL and PI-PL lots to support expansion of the same MSC populations
MSC PL or PI-PL P1 P3 Fold Expansion* Doubling
Time (hours)°Day to reach MSCx106§ Day to reach MSCx106#
MSC-1 PL1 16 0.847 27 142 168 35.7
PI-PL1 16 0.765 27 120 157 36.2
MSC-3 PL1 16 0.572 31 182 319 43.3
PI-PL2 16 0.564 31 177 313 43.4
MSC-6 PL1 15 1.150 27 116 97 43.3
PI-PL3 15 1.264 27 162 128 41.1
MSC-3 PL2 15 0.933 32 204 219 52.5
PI-PL1 15 0.950 32 212 223 52.3
MSC-4 PL2 13 0.560 31 101 181 57.6
PI-PL2 13 0.638 31 77 177 62.5
MSC-7 PL2 15 0.570 27 46 81 45.5
PI-PL3 15 0.563 27 83 148 40
MSC-5 PL3 12 0.940 30 144 154 59.5
PI-PL1 12 0.948 30 117 123 62.2
MSC-6 PL3 13 1.056 31 100 95 65.8
PI-PL2 13 0.899 31 103 115 63.2
MSC-8 PL3 13 0.970 32 109 112 66.9
PI-PL 3 13 1.155 32 113 98 68.9
PL platelet lysate, PI-PL pathogen inactivated platelet lysate, MSC mesenchymal stem cells, P1 passage 1 of culture, P3 passage 3 of culture; different MSC
populations (1,3,4,5,6,7,8) were obtained by the culture of a starting number of 5 × 106 mononuclear cells from as many bone marrow samples.
§p = 0.640 and #p = 0.802 at paired two-tailed Student’s T test between MSC growth promoted by control PL and PI-PL lots. *fold expansion at P3 as compared to
cells obtained at P1, p = 0.541 at paired two-tailed Student’s T test between MSC expansion promoted by control PL and PI-PL lots. °doubling time measured as
hours between P1 and P3 for each MSC population, p = 0.975 at paired two-tailed Student’s T test between control PL and PI-PL lots.
Figure 6 MSC growth in the presence of fetal bovine serum (FBS) or PL/PI-PL lots. Growth of three MSC populations (MSC9, MSC180,
MSC082) at passage1,2,3 (P1,P2,P3) in the presence of PL1, PI-PL11, PI-PL16, PI-PL43/44 and FBS, expressed as the absolute number of cells
obtained in cultures in D-MEM medium. Cell number, expressed by a logarithmic scale, shows in any case an irrelevant effect of FBS on MSC
growth when used as a supplement of a basic culture medium.
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Figure 7 Cryopreserved MCS expansion by Pl or PI-PL. Re-expansion of cryopreserved MSC11,12,170,180 and 082 by control PL1, PL18 and
PI-PL1, PI-PL18 expressed as doubling time (DT) observed between passage 3 (P3) and 4 (P4). Two-tailed paired Student’s T test performed
between PL1 versus PI-PL1 and PL18 versus PI-PL18 lots shows no significant differences.
Figure 8 Comparison of growth factor concentration and growth promoting-ability between PL18 and PI-PL18. PL18 and PI-PL18 were
generated by the same initial lot (omitting PI step in PL18 preparation) and were compared to assess the impact of PI on growth factors and MSC growth
in a head to head comparison. a) growth factor concentrations were evaluated in triplicates for both samples and compared by two-tailed paired
Student’s T test which shows no significant differences; b) MSC170, MSC180, MSC082 MSC11 populations were grown in parallel in the presence of either
PL18 or PI-PL18; cell growth was expressed as doubling time (DT) between passage 1 (P1) and passage 2 (P2). Statistical analysis by two-tailed paired
Student’s T test between PL18- or PI-PL18-induced growth on different MSC populations shows no signficance in the direct comparison.
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Figure 9 Flow cytometric analysis of MSC6 cultured with PI-PL2. A representative example of flow cytometric analysis of MSC6 population
at P1 obtained from a culture established in the presence of PI-PL2. Dot plots a), b), and c) show co-expression of typical MSC markers on the
majority of analysed cells with the absence of CD45 and CD34 haemopoietic cell markers. Dot plot d) shows a typical analysis to evaluate MSC
viability by 7-AAD staining associated with the expression of CD105 constitutive antigen.
Table 3 Antigenic analysis by flow cytometry of MSC




CD105+% CD90+% CD71+% CD73+%
P1@ P3* P1§ P3# P1+ P3^ P1° P3_
MSC-1 PL1 92 98 92 98 95 99 95 99
PI-PL1 94 99 92 99 95 100 95 100
MSC-3 PL1 93 98 94 98 95 99 95 99
PI-PL2 93 95 90 90 95 98 95 98
MSC-6 PL1 94 96 93 99 94 99 94 99
PI-PL3 91 98 94 98 95 99 95 99
MSC-3 PL2 94 97 91 97 92 98 92 98
PI-PL1 94 97 95 98 95 99 95 99
MSC-4 PL2 93 96 92 98 94 99 90 99
PI-PL2 93 98 92 97 94 99 94 99
MSC-7 PL2 93 96 91 99 92 98 95 99
PI-PL3 92 96 94 98 95 98 95 98
MSC-5 PL3 90 96 90 98 94 99 94 99
PI-PL1 93 98 92 98 94 99 94 99
MSC-6 PL3 93 97 95 99 90 98 92 99
PI-PL2 92 98 94 99 94 99 94 99
MSC-8 PL3 92 99 94 98 95 99 93 96
PI-PL 3 90 99 92 97 94 99 90 98
PL platelet lysate, PI-PL pathogen inactivated platelet lysate, MSC mesenchymal
stem cells, P1 passage 1 of culture, P3 passage 3 of culture; CD34 and CD45
expression was consitently lower than 5% in all cultures at any time point.
Each antigen is expressed as percentage of positive cells detected at P1 and
P3 in each flow cytometric analysis performed on different MSC populations
(1,3,4,5,6,7,8) which were grown in the presence of the indicated PL or PI-PL.
@p = 0.833, *p = 0.402, §p = 0.615, #p = 0.254, +p = 0.095, ^p = 0.346, °p = 0.287
and _p= 0.512 at paired two-tailed Student’s T test between antigen expression
in cultures supported by control PL and PI-PL lots.
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was respectively 16 (PL) and 19 (PI-PL), on average.
Flow cytometric analysis and differentiation properties of
cultured MSC
Flow cytometric analysis carried out on initial MNC
from 14 BM samples showed that the MSC-associated
phenotype, such as CD45-, CD34-, CD105+, CD90+, CD73+,
CD71+, CD166+, was rarely expressed among these cells
(<0.05%), whereas at P1 more than 95% of the cells homo-
geneously expressed the MSC phenotype, in cultures ad-
ditioned with both control PL and PI-PL. Comparable
expression of MSC surface antigens was observed in all
cultures at different passages with a cell viability never
lower than 90% at any time point. A representative flow
cytometry analysis at P1 of MSC 6 cultured in the pres-
ence of PI-PL2 is shown in Figure 9 (a-d). Table 3 gives in
detail the expression of constitutive antigens of MSC, in
head to head experiments between different lots of PL
and PI-PL, tested on MSC1, MSC3, MSC4, MSC5, MSC6,
MSC7 and MSC8.
As to the MSC multilineage differentiation potential,
our results demonstrate that fresh or thawed MSC cul-
tured in proper media, additioned with PL or PI-PL lots,
were able to initiate differentiation into osteoblasts, adipo-
cytes and chondrocytes. Figure 10 (a) 1-3 staining controls
of undifferentiated MSC; b)1, c)1 osteogenesis; b)2, c)2 ad-
ipogenesis; b)3, c)3 chondrogenesis] shows the results of a
representative experiment obtained by inducing differenti-
ation of MSC 6 pre-expanded in the presence of PL3 or
PI-PL3. Differentiation analysis was performed by specific
tissue staining and microscope examination.
MSC immunoregulatory effect
To test whether PI procedure could affect the immuno-
suppressive activity of MSC, one-way MLC and PHA in-
duced proliferation assays were established. Figure 2 (a)
shows a typical CFSE dilution profile following a prolif-
eration stimulus in MLC, in the absence of any inhibi-
tory effect; in the presence of MSC, most of proliferatingcells fall into the first generation peak and do not move
to the second one (b,c), as result of MSC immunosup-
pressive action. A proliferative inhibition ranging be-
tween 13% and 75% was found both in culture with PL
or PI-PL derived MSC and the higher suppression of cell




a) Controls b)  PL-3 c)  PI-PL3 
Figure 10 MSC differentiation. Multilineage differentiation documented by specific tissue staining and by microscope examination after
differentiation of MSC 6 pre-expanded in the presence of PL3 (b) and PI-PL3 (c); a-(1-3) pictures are controls of cell staining in the absence of
differentiating stimulus; b-(1-3) pictures represent osteoblast, adypocyte and chondrocyte differentiation of PL3-derived MSC6; c-(1-3) pictures
represent osteoblast, adypocyte and chondrocyte differentiation of PI-PL3-derived MSC6.
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cells to MSC of 20/1 (Figure 2d). The inhibition of cell
proliferation induced by PHA, in the presence of both
PL-derived MSC and PI-PL-derived MSC (using a ratio
of proliferating cells to MSC of 20/1 without stimulator
cells) occurred to a less extent, ranging between 12%-
25% (Figure 2d). Moreover, co-culture of PL-MSC or PI-
PL-MSC with allogeneic PBMC highly increased the ex-
pression of CD25+ on CD4+ proliferating lymphocytes
and induced the expansion of Treg Foxp3+ cells within
CD25+ T subset, which are known to exhert immu-
nosuppressive capacity. Figure 3 presents the dot plots
of a representative experiment carried out on PBMC,
cocultured with or without PI-PL3-derived MSC8, show-
ing higher induction of CD4+/25+/FoxP3+ cells in the
presence of MSC at a PBMC/MSC ratio of 20/1.
Conclusions
The use of animal sera for clinical-scale MSC expansion
raises concerns because of the risk to transmit prions,
viruses or to induce immunological reactions in recipi-
ents following infusion and for these reasons these prod-
ucts are not allowed in good manufacturing practice
(GMP) applied to cell therapy. Therefore, culture sup-
plements derived from humans have been investigated
in order to replace animal serum in MSC cultures.Human AB blood serum and umbilical cord blood
serum have been found to provide a stimulus for MSC
growth comparable to animal serum or higher with the
preservation of MSC capacity to differentiate in three
different mesodermal lineages [21]. Human PL is cur-
rently under investigation for its ability to sustain ex vivo
MSC growth and data have been reported comparing
the efficacy of PL with animal serum in promoting MSC
expansion in the setting of cell-therapies [14-16]. From
these evidences appear that PL is a powerful substitute
of animal serum and its use may contribute to amelior-
ate the safety of MSC-based products in terms of im-
munological side effects and xenogenic pathogen
transmission. PL properties are based on the release of
growth factors by PLT which play a physiological role in
the wound healing process. The content of PDGF-AB,
TGF-β1 and bFGF in PL may account for its efficacy in
promoting MSC growth since these cells have been
shown to express surface receptors for PLT derived fac-
tors [14]. Nevertheless, procedures to prepare PL are
highly variable and although this human source is rigor-
ously screened for potential infectious threats, the risk of
disease transmission by human derived products still re-
quires careful consideration. In this study, a standardized
procedure to generate PL by pooling multiple units of BC-
derived PLT is described. The protocol includes a step of
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tinely applied practice for production of PLT concentrates
for transfusional use in European countries [22], and the
final resuspension of the PLT product in AS with a mini-
mum residue of plasma (20-30%), as compared to the ori-
ginal products. PI technology by exposure to psoralen
compound and UVA light has been found effective in in-
activating a broad panel of viruses and bacteria without
compromising PLT hemostatic function [23] and, there-
fore, PI-PL may represent a safer product for ex vivo MSC
expansion to generate clinical grade cells for therapeutic
strategies. However, a relevant issue is that to investigate
whether pathogen reduction step may affect PL in its abil-
ity to generate ex vivo MSC. Here, the results of growth,
expansion, differentiation and immunosuppressive func-
tion of several MSC populations cultivated in medium sup-
plemented with both PL and PI-PL showed comparable
features and growth potential. Differences between the
various preparations, even though not relevant, may de-
pends on the individual variability in PLT growth factor
content. To obtain a more standardized PL preparation, we
generated PI-PL by a pooling procedure which combined
12 PLT units, starting from 2 initial pools of 6, being six
the maximum number of units which may be pooled for
the PI step by the Intercept technology. An additional ad-
vantage of PI-PL preparation is the very low amount of re-
sidual plasma which may prevent the occurrence of
immunological adverse reactions, often related to the pres-
ence of this human component. Some authors produced a
plasma-free PL in human albumin solution, called PL-HA,
for in vitro expansion of MSC [24,25]. The authors showed
that MSC expanded in medium supplemented with PL-
HA proliferated more extensively with respect to cultures
additioned with FBS or conventional PL. In the same con-
text, Burnouf et al. and Shih et al. [26,27] developed a vir-
ally inactivated PL for cell cultures by a solvent detergent
procedure for viral inactivation, followed by oil extraction
and adsorption with activated charcoal or soybean oil ex-
traction and centrifugation, respectively. These prepara-
tions had been tested in growing cell lines, as MG63 and
SIRC, and for selection and expansion of adipose tissue
MSC. Neverthless, these studies reported that PDGF-AB
and VEGF were completely removed by the adsorption
step with charcoal as well as bFGF was partially removed
by soybean oil extraction; from this evidence we may argue
that these products are not completely suitable for MSC
growth due to the well-described action of these growth
factors in supporting optimal MSC expansion.
In a recent work Fekete et al. [28] produced PL from
pool of 4 PLT units irradiated and quarantined for at least
4 months. The authors released the PLT units for PL
production only if the all four donors contributing to a
PLT pool had tested again as negative for conventional
transfusion-transmitted infectious diseases. This approachto guarantee a safer clinical grade PL requires a longer
storage of the starting material before PL preparation and
is depending on the donor comeback for control testing.
The addition of PI may further contribute to the safety of
PL preparation by covering also the potential risk of new
emerging infectious agents. Actually, over recent years the
threat of transfusion transmitted agents focuses the atten-
tion on emerging pathogens which can be present in the
blood and may concern public health, as the case of West
Nile Virus [29]. Testing donation for evidence of a new
pathogen may be adopted when the test become available
and is validated for donor screening. Therefore, pathogen
reduction could be considered the prompt approach to
struggle with emerging infection transmissible via blood.
Cell amplification by ex-vivo cultures, in the presence of
human or animal blood components, is not a process free
from the potential risk of transmission of infectious dis-
ease or immunological reactions; hence, the safety of this
procedure may be greatly improved by the use of a human
plasma-poor standardized product, contained in lots with
a known growth factor content and subjected to an effect-
ive PI process. In this setting, PI-PL preparations repre-
sent a safe plasma-poor, well-standardized platelet lysates,
prepared in lots which may be characterized for growth
factor content and specific functional activity; these prepa-
rations had been improved in their quality grade by adding
PI step and, for these reasons, appear as ideal supplements
to develop uniform and well standardized protocols for
ex vivo expansion of MSC without affecting antigenic and
functional characteristics of these cells, as may happen
with some serum-free commercial media [30].
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